The impact of stent design and delivery upon the long-term efficacy of radioisotope stents.
Both gamma and beta irradiation delivered via a radioactive catheter-based line source have been shown to have efficacy in reducing restenosis. However, these catheter-based treatments have some limitations, including the safety of handling sources ranging from 30 mCi to 500 mCi. Alternatively, one could use a stent as the platform for local radiation delivery as a means to prevent restenosis. Experimental studies have demonstrated that stents ion implanted with the b-particle emitter 32P can reduce neointima formation. Clinical evaluation of the radioisotope stent began in the fall of 1996. Dose escalation studies have now been completed in approximately 250 patients with 32P, b-particle emitting stents ranging from 0.5 microCi to 24 microCi. Overall, these feasibility trials have demonstrated a clear, dose-dependent reduction of neointimal hyperplasia within the stent structure, but with an unanticipated finding of a relatively high incidence of restenosis at the stent margins. The purpose of this paper is to review the current status of radioactive stents, with an emphasis on the key elements of stent design and stent delivery that could impact the long-term efficacy of this device.
Fischell
T A
TA
Director, Heart Institute at Borgess Medical Center, 1521 Gull Road, Kalamazoo, MI 49001, USA. tafl@net-link.net.
Hehrlein
C
C
Fischell
R E
RE
Fischell
D R
DR
D001918:Brachytherapy / Q000295:instrumentation*; D017023:Coronary Angiography; D003327:Coronary Disease / Q000532:radiotherapy*; D004307:Dose-Response Relationship, Radiation; D004867:Equipment Design; D005240:Feasibility Studies; D006801:Humans; D010761:Phosphorus Radioisotopes / Q000008:administration & dosage; D011879:Radiotherapy Dosage; D012008:Recurrence; D015607:Stents
D010761:Phosphorus Radioisotopes